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The results of good randomized controlled trials (RCTs) published in leading peer-reviewed journals have been deemed
the best possible basis for good medical practice. However, several limitations may decrease their value. These include
ﬂaws and weaknesses in the design and the timeliness of RCTs. Progress in a treatment method or control arm may
invalidate a trial. So too can defects in patient selection, physician competence, randomization, applicability, end points,
and the population being studied. Idiosyncratic ﬂaws can also invalidate an RCT. Examples of these ﬂaws and weaknesses
are presented. Another problem with articles describing RCTs is the potential for the conclusions of the trial report to be
misleading because of error or bias. This plus subsequent misinterpretation of the trial results or conclusions by others
can make the effect of the trial misleading with an unintended detrimental result on medical practice. Guidelines based on
such errors or bias-based conclusions and misinterpretations can further compound the problem. This article provides
examples of misleading conclusions and/or misinterpretations (spinning) of trial results in articles describing RCTs in
leading journals. All physicians should recognize these value-limiting processes so that RCTs can be evaluated adequately
and fairly. In that way, they can be used along with good physician judgment to optimize the care delivered to individual
patients and to society at large. (J Vasc Surg 2013;57:3S-7S.)It is widely recognized that peer-reviewed articles in
leading journals inﬂuence medical practice. These journals
include the New England Journal of Medicine, Lancet, the
Journal of Vascular Surgery, Circulation, the European
Journal of Vascular and Endovascular Surgery, the Journal
of Endovascular Therapy, the Journal of Vascular and Inter-
ventional Radiology, andmany others. Articles in these jour-
nals form the scientiﬁc basis for what vascular surgeons and
other vascular specialists do in the management of patients
with noncardiac vascular disease. It is assumed that these
journals are peer reviewed and edited with objectivity and
that their content is unbiased and reﬂects the truth or
near truth. Collectively, these journals and their relevant
articles represent the bible of vascular disease management,
vascular surgery, and other vascular specialties.
Randomized controlled trials (RCTs) when reported in
these journals are considered part of level 1 evidence or the
“holy grail” of medical evidence.1 Such trials are deemed
by many as close to the truth as one can get and the best
possible basis for determining medical practice.
This article shows why this is not always the case and
how RCTs, even when reported in leading journals, can
be misleading by two mechanisms. The ﬁrst is by timelinessthe Divisions of Vascular Surgery, New York University Medical
enter, New York; and The Cleveland Clinic, Cleveland.
or conﬂict of interest: none.
n as the Robert B. Rutherford Award Lecture at the Fifth Annual
eeting of the World Federation of Vascular Societies, Chicago, Ill,
ne 15, 2011.
rint requests: Frank J. Veith, MD, 4455 Douglas Ave, Bronx, NY 10471
-mail: fjvmd@msn.com).
editors and reviewers of this article have no relevant ﬁnancial relationships
disclose per the JVS policy that requires reviewers to decline review of any
anuscript for which they may have a conﬂict of interest.
-5214/$36.00
yright  2013 by the Society for Vascular Surgery.
://dx.doi.org/10.1016/j.jvs.2012.04.076or design ﬂaws in the RCTs. The second is by misinterpre-
tation of even well-designed valid RCTs so that they are
rendered misleading. This can occur when the conclusion
expressed in the article reporting the RCT is inconsistent
with the trial’s data because of error or bias in interpreting
the trial results. It can also occur when others interpret the
results of a trial in an erroneous or biased fashion. An addi-
tional purpose of this article is to show how guidelines
based on ﬂawed or misinterpreted RCTs can also be
misleading and harmful to good patient care.
PERSPECTIVE ON RANDOMIZED
CONTROLLED TRIALS AND LEVEL 1
EVIDENCE
There is legitimate disagreement about the need for
and the value of level 1 evidence to support various aspects
of medical practice. Some believe practice should always be
based on the support of level 1 evidence and good RCTs.
However, because of the ﬂaws and weaknesses in RCTs
and because they are hard to do, others believe that such
level 1 evidence support is rarely needed. Both these view-
points have some merit. Although good, valid RCTs can be
an excellent basis for determining medical practice, their
possible ﬂaws and weaknesses must always be recognized
and considered. RCTs and level 1 evidence are not always
absolute, inviolate, or timeless. Appropriate evidence-based
information or guidelines may not always be available,
applicable, or correct. Accordingly, physician judgment
must be exercised in the application of RCTs to clinical
decisions in various circumstances and will always be
required for the optimal practice of medicine.
FLAWS AND WEAKNESSES OF RANDOMIZED
CONTROLLED TRIALS
These ﬂaws and weaknesses are divided into two groups
as outlined in Table I, which also provides examples.3S
Table I. Flaws and weaknesses of randomized controlled trials that render them less applicable or invalid
Flaw/weakness Example
1. Treatment under evaluation technology or patient selection
improves
CAS vs CEA RCTs (EVA-3S2 and others)
2. Progress in control treatment Asymptomatic CS-CEA þ BMT vs BMT RCTs (ACAS,3 ACST4)
3. Poor or unrepresentative patient selection CAS vs CEA (SAPPHIRE5,6)
4. Inadequate experience or competence of operators CAS vs CEA-CAS operators (EVA-3S,2 ICSS7)
CEA operators (SAPPHIRE5)
5. Imperfect randomization (SAPPHIRE5—see text)
6. Nonapplicability to reality CAS vs CEA (CREST8—see text)
7. Idiosyncratic ﬂaws: delay in application of treatment Endovascular abdominal aortic aneurysm repair vs no treatment in
unﬁt patients (EVAR 211)
8. Imperfect population randomized CAS vs CEA: asymptomatic patients included, power decreased
(CREST8)
9. Inappropriate primary end points CAS vs CEA: myocardial infarction included (SAPPHIRE,5
CREST8)
ACAS, Asymptomatic Carotid Atherosclerosis Study; ACST, Asymptomatic Carotid Surgery Trial; BMT, best medical therapy; CAS, carotid artery stenting;
CEA, carotid endarterectomy; CREST, Carotid Revascularization Endarterectomy Versus Stenting Trial; CS, carotid stenosis; EVA-3S, Endarterectomy
Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis; EVAR 2, Endovascular Abdominal Aortic Aneurysm Repair 2; ICSS, International
Carotid Stenting Study; RCT, randomized controlled trial; SAPPHIRE, Stenting and Angioplasty with Protection in Patients at High Risk for
Endarterectomy.
JOURNAL OF VASCULAR SURGERY
4S Veith February Supplement 2013Timeliness ﬂaws. In the simplest terms, RCTs usually
compare a new treatment against an old treatment or a new
treatment against no treatment. In each instance, the treat-
ment under evaluation is compared in randomized fashion
against a control arm (old treatment or no treatment). If
in an RCT, the new treatment is proven to be ineffective,
and then the technology, patient selection, or operator skills
for the new treatment improve in a major way, the original
RCT becomes obsolete or invalid on the basis of timeliness
(Table I, item 1). An example would be the Endarterec-
tomy Versus Angioplasty in Patients with Symptomatic
Severe Carotid Stenosis (EVA-3S) trial in which carotid
stenting (CAS) proved to be less safe and yield worse
outcomes than carotid endarterectomy (CEA).2 With
improvements in CAS technology, patient selection, and
operator experience and skill, the conclusions of this trial
may no longer be valid.
On the other hand, if there is a valid RCT proving
a given treatment effective against a control arm and there
is improvement in the latter, the conclusions of the trial
become obsolete and no longer valid. Examples would be
trials comparing CEA and best medical therapy (BMT)
against a control group receiving BMT alone, like the
Asymptomatic Carotid Atherosclerosis Study (ACAS) and
Asymptomatic Carotid Surgery Trial (ACST).3,4 Because
BMT for stroke prevention has improved dramatically since
patients were entered into these trials (up to 2003), the
demonstration that CEA plus BMT is better than current
BMT alone is no longer valid (Table I, item 2).
Design ﬂaws. Inappropriate patient selection for
randomization can invalidate the conclusion of an RCT.
An example of this ﬂaw was in the Stenting and Angio-
plasty with Protection in Patients at High Risk for Endar-
terectomy (SAPPHIRE) trial comparing CAS with CEA
in high-risk patients with carotid stenosis (CS).5 Patients
were selected for randomization because they were at highrisk for CEA but not necessarily for CAS, thus biasing the
study against the open surgical procedure.6 SAPPHIRE
had the additional ﬂaw of including 71% asymptomatic
patients and yet having unacceptably high 30-day stroke
and death rates (w6%).6
The competence and experience of the operators per-
forming the treatment under evaluation can be suboptimal.
If this is true, the conclusions of the RCT can be invalid or
at least open to question. Some have made the case that
such experience and competence issues have impaired the
validity of the EVA-3S and International Carotid Stenting
Study (ICSS) trials, which compare the outcomes of CAS
and CEA in symptomatic patients with CS.2,7 Whether or
not these issues invalidated these trials remains
controversial.
Adequacy of patient randomization is another issue
that can weaken or invalidate the conclusions of RCTs.
SAPPHIRE is one example, as many more patients were
excluded from randomization and treated by CAS than
were randomized to the CAS arm.
If the operators who perform the procedure under
evaluation in an RCT are so experienced and skillful that
they are not representative of the vascular specialists per-
forming the procedure in the population at large, then
the results of the trial cannot apply to the general popula-
tion of patients who are treated by less skilled operators. In
the Carotid Revascularization Endarterectomy Versus
Stenting Trial (CREST) trial, those performing CAS were
only vetted to enter patients after they were shown to
have a high level of experience and skill.8 Thus, the CAS
results in CREST may not be representative of those gener-
ally performing the procedure in the “real world.” This
possibility is supported by the higher adverse event rates
with CAS in population-based studies than in CREST.8-10
Some RCTs are weakened or invalidated by idiosyn-
cratic ﬂaws that are speciﬁc to the trial. One example of
Table II. Data details from the Carotid
Revascularization Endarterectomy Versus Stenting Trial
(CREST)8
Adverse event
No. of
CAS-treated
patients
(n ¼ 1262)
No. of
CEA-treated
patients
(n ¼ 1240) P value
Deaths 9 4 .18
Total strokes 52 29 .01
Major strokes (ipsilateral) 11 4 .09
Minor strokes (ipsilateral) 37 17 .01
Minor myocardial infarctions 14 28 .03
CAS, Carotid artery stenting; CEA, carotid endarterectomy.
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Aneurysm Repair 2 (EVAR2) trial in which endovascular
abdominal aortic aneurysm repair (EVAR) was compared
with no treatment in patients deemed unﬁt for open repair.
A major ﬂaw in this trial was the lengthy delay after
randomization to EVAR (average, 57 days) until the proce-
dure was performed.11 During that delay, nine of the
patients died from aneurysm rupture before having the
scheduled EVAR. The trial showed no difference in
mortality between the two groups. The conclusion reached
was that EVAR offered no beneﬁt in these unﬁt aneurysm
patients.11 If the nine patients who died from rupture
before their scheduled EVAR was performed had been
treated promptly, the trial’s results would likely have
been very different.
Some otherwise excellent and valid RCTs are nega-
tively impacted by inclusion of inappropriate patients in
the randomization process. One example of this was in
CREST, which included both symptomatic and asymptom-
atic patients (see below).8 Many believe that symptomatic
CS and asymptomatic CS are somewhat different disease
processes with different plaque characteristics, embolic
potential, and stroke potential. Because of the inclusion
of the asymptomatic patients, the statistical power of the
ﬁndings in CREST was reduced and the value of the study
was weakened.
Finally, the choice of inappropriate end points for deter-
mining safety and efﬁcacy of the treatment under evaluation
may weaken some otherwise good RCTs. Inclusion of
myocardial infarction (MI) as part of a composite adverse
event rate end point in CAS vs CEA trials (SAPPHIRE
and CREST) is an example.5,8 Although the case may be
made for or against this inclusion, whether or not MIs are
equivalent to strokes remains controversial, especially
because the primary purpose of both CAS and CEA is to
prevent death and disability from strokes. All of these ﬂaws
and weaknesses can reduce the value of an RCT or invalidate
it completely. They must be considered in using and
applying RCTs to clinical situations.
BIASED OR ERRONEOUS CONCLUSIONS AND
INTERPRETATIONS OF RCTs
There is an even more insidious problem with some
RCTs. This is the impact of bias in the interpretation of
trial results that unfairly alter the conclusions reached in
the article reporting the trial. These biased or erroneous
conclusions can appear directly in articles describing
RCTs with some of the ﬂaws and weaknesses already dis-
cussed. Even more importantly, such biased and misleading
conclusions can be reached in reports of otherwise ﬂawless
studies published in the foremost journals. Because of the
high regard in which these exemplary RCTs are held,
such misleading conclusions may have an important detri-
mental inﬂuence on medical practice.
This problem can be further enhanced by a second
usually bias-related mechanism, namely, the way RCTs and
their conclusions can be misinterpreted or “spun” by others
to support their special interests. Suchmisinterpretations caneven ﬁnd their way into guideline documents produced by
respected professional societies.
To exemplify these issues, this article presents a detailed
analysis of CREST and a more superﬁcial overview in
tabular form of several other highly respected RCTs that
have been reported in leading peer-reviewed and widely
read journals.
CREST was designed to compare CAS and CEA in
symptomatic patients with CS.8 CREST has been regarded
as a well-designed, well-conducted, exemplary RCT. Some
have claimed that its results changed everything in the ﬁeld,
and it has been spun beyond that. In this regard, CREST
formed the basis for an important part of the so-called
American Heart Association (AHA) Guideline on Manage-
ment of Patients With Extracranial Carotid and Vertebral
Artery Disease, which was also approved by 13 other orga-
nizations.12 This guideline reached the conclusion that
“CAS is indicated as an alternative to CEA for symptomatic
patients at average or low risk of complications associated
with endovascular intervention.”12
Let us examine the facts and data in CREST to see if its
conclusions are justiﬁed and, more importantly, if the way
CREST is being interpreted in the AHA Guideline and
spun by others is reasonable and valid. CREST, conceived
in 1997 and funded by the National Institutes of Health in
1999, randomized and analyzed 2502 patients from 2000
to 2008. It was originally designed to compare CAS and
CEA for the treatment of moderate and high-grade CS
in recently symptomatic (6 months) patients. Because
adequate numbers of patients could not be recruited,
asymptomatic patients were included in 2005. The 4-year
results in 1262 CAS-treated patients and 1240 CEA-
treated patients were reported in June 2010.8
The primary safety end point was a composite of death,
stroke, and MI. This end point was reached by 4 years in
7.2% of the CAS patients and 6.8% of the CEA patients
(P ¼ .51). The conclusions reached in the NEJM report
was that the risk of CAS and CEA “did not differ signiﬁ-
cantly” in patients with symptomatic and asymptomatic
CS. Because of this conclusion, CREST is being spun to
demonstrate the equivalence of CAS and CEA in both
symptomatic and asymptomatic CS patients. In addition,
the AHA Guideline implies that this is the case.
Table III. Other randomized controlled trials that reached misleading conclusions
RCT
Publication
site Year Trial conclusion Flaws Appropriate conclusion
ACAS
ACST
JAMA
Lancet
19953
20104
CEA decreased SR more than
BMT; CEA for ACS reduces
10-year SR from 2% to 1% per
year
Obsolete BMT; decreasing SR
with ACS
Need RCT in ACS of CAS and
CEA vs BMT; need way to
identify high-SR patients;
BMT best for most ACS
patients
SAPPHIRE NEJM
NEJM
20045
200814
No signiﬁcant difference in
outcome of CAS and CEA
at 30 days, 1 year, or 3 years
71% asymptomatic CAS
patients; w6% 30-day SR
High-risk ACS patients should
be treated with BMT, not by
CAS or CEA
EVAR 2 Lancet 200511 In unﬁt patients, EVAR did not
improve survival over no
intervention
Half of deaths (9) in EVAR arm
were caused by rupture be-
fore treatment, average
delay ¼ 57 days
Timely EVAR justiﬁed in some
unﬁt patients (see text)
EVAR 1 NEJM 201017 EVAR and open repair yielded
equivalent long-term mor-
tality with increased graft
complications, need for
reinterventions, and cost
EVAR prolonged patient sur-
vival longer than open repair
ACAS, Asymptomatic Carotid Atherosclerosis Study; ACST, Asymptomatic Carotid Surgery Trial; ACS, asymptomatic carotid artery stenosis; Trial; BMT, best
medical therapy;CAS, carotid artery stenting;CEA, carotid endarterectomy;CREST,Carotid Revascularization Endarterectomy Versus Stenting Trial; EVA-3S,
Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis; EVAR, endovascular abdominal aortic aneurysm repair; EVAR 1 (2),
Endovascular Abdominal Aortic Aneurysm Repair 1 (2) study; JAMA, Journal of the American Medical Association; NEJM, New England Journal of Medicine;
RCT, randomized controlled trial; SAPPHIRE, Stenting and Angioplasty With Protection in Patients at High Risk for Endarterectomy; SR, stroke rate.
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ment, one must examine in greater detail the data from
CREST and its ﬂaws (some already mentioned), remem-
bering that the purpose of CEA and CAS is to prevent
strokes, disability, and death from CS. Table II lists some
of the data details from CREST. There were substantially
more deaths and strokes in the CAS-treated patients than
in the patients treated by CEA. Only when MIs were
included were the adverse events similar in the two groups.
Other ﬂaws in CREST existed (some already men-
tioned). Adding asymptomatic CS patients to the study
diluted its power and prevented signiﬁcance from being
reached in some of the adverse events listed in Table II.
The composite end point weakened the trial. MIs are
not the equivalent of strokes. This is borne out by the greater
degree of disability after a stroke than an MI observed
in many studies including CREST. Moreover, even
after a minor stroke with full motor and sensory recovery,
patients often have evidence of brain damage with loss of
memory and intelligence and altered affect. Although it
has been pointed out that even minor MIs are associated
with decreased life expectancy, and this was observed in
CREST,13 the same is true after minor strokes, and this
was documented in CREST. Although further subgroup
analyses from CREST may be enlightening, and although
everyone is entitled to have their bias, the detailed CREST
data in Table II seem to speak for themselves.
In addition to those already discussed, there is another
possible ﬂaw in CREST. The CAS-treated patients received
more intensive antiplatelet therapy during and after their
procedure than did the CEA-treated patients. This may
have contributed to the decreased incidence of MIs in
the CAS group.So what is the value of CREST, and how should it be
used? It clearly shows that both CAS and CEA can be per-
formed with low morbidity and mortality rates. However,
CREST, like most RCTs, has its ﬂaws, which must be
considered in any interpretation of its results. Moreover,
CREST should be considered with other RCTs comparing
CAS with CEA in symptomatic CS patients, particularly the
most recent European trial, the ICSS.7 Although the latter
trial may also have its ﬂaws, it showed that CAS was asso-
ciated with a higher stroke rate and more diffusion-
weighted magnetic resonance imaging cerebral defects
than CEA. However, in both the International Carotid
Stenting Study and CREST, the CAS procedures did not
reﬂect the current state of the art. Accordingly, it is likely
that with better stents (membrane or mesh covered), better
embolic protection (reversal or cessation of ﬂow), better
patient selection, and better operator skills, the results of
CAS will be better than they were in these two most recent
good trials. However, this must be shown by appropriate
future RCTs.
With respect to asymptomatic patients, CREST does
not add much, as it did not include a BMT arm. A trial
that does include the latter is sorely needed. Until then,
and until we can have better methods to identify asymp-
tomatic CS patients at high risk of having a stroke, it is
likely that many, if not most, such patients should be
treated with BMT and undergo no invasive intervention.
However, this remains highly controversial.
What about the AHA Guideline and its conclusion,
based largely on CREST, that “CAS is an alternative to
CEA” in symptomatic average- and low-risk patients? A
Webster’s Dictionary deﬁnition of alternative is “choice
between two things.”15 This implies equivalence. In view
JOURNAL OF VASCULAR SURGERY
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Table II, it would seem that the AHA Guideline’s conclu-
sion that CAS is an alternative to CEA is not yet justiﬁed
except when there are clear contraindications to CEA in
a symptomatic patient requiring invasive treatment.16
High or long lesions or infected, scarred, or immobile
necks represent examples of such contraindications.
Finally, what about some other RCTs published in
leading journals and how they may be misleading? Some
of these, their stated conclusions, more appropriate conclu-
sions, and their date and site of publication are summarized
in Table III. The most misleading of these trials was
SAPPHIRE, a deeply ﬂawed trial, which was published
twice in the NEJM and spun widely at medical meetings
and in the lay press to spell the death knell of CEA.5,6,14
CONCLUSIONS
All these RCTs show that unjustiﬁed conclusions can
sometimes be reached in leading peer-reviewed journals.
This occurs because of ﬂaws in the RCTs, unrecognized
author bias, or both. More importantly, these unjustiﬁed
conclusions and the trials on which they are based can be
further misinterpreted or spun to reach even more erro-
neous or unjustiﬁed conclusions. Presumably, much of
this spinning results from the bias or biases that all of us
in medicine have. By being aware of the inﬂuence of bias
along with the possible ﬂaws that RCTs can have, we
should be able to interpret and use RCTs fairly and opti-
mally for the care of patients.
REFERENCES
1. Sackett DL, Rosenberg WM. The need for evidence-based medicine.
J R Soc Med 1995;88:620-4.
2. Mas JL, Chatellier G, Beyssen B, Branchereau A, Moulin T,
Becquemin JP, et al, for the EVA-3S Investigators. Endarterectomy
versus stenting in patients with symptomatic severe carotid stenosis.
N Engl J Med 2006;355:1660-71.
3. Executive Committee for the Asymptomatic Carotid Atherosclerosis
Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA
1995;273:1421-8.
4. Halliday A, Harrison M, Hayter E, Kong X, Mansﬁeld A, Marro J, et al,
for the Asymptomatic Carotid Surgery Trial (ACST) Collaborative
Group. 10-year stroke prevention after successful carotid endarterec-
tomy for asymptomatic patients (ACST-1): a multicentre randomised
trial. Lancet 2010;376:1074-84.
5. Yadav JS, Wholey MH, Kuntz RE, Fayad P, Katzen BT, Mishkel GJ,
et al, for the Stenting and Angioplasty with Protection in Patients at
High Risk for Endarterectomy Investigators. Protected carotid-artery
stenting versus endarterectomy in high-risk patients. N Engl J Med
2004;351:1493-501.
6. Naylor AR, Golledge J. High risk plaque, high risk patient or high risk
procedure? Eur J Vasc Endovasc Surg 2006;32:557-60.7. Ederle J, Dobson J, Featherstone RL, Bonati LH, van der Worp HB,
de Borst GJ, et al, for the International Carotid Stenting Study
Investigators. Carotid artery stenting compared with endarterectomy in
patients with symptomatic carotid stenosis (International Carotid
Stenting Study): an interim analysis of a randomised controlled trial.
Lancet 2010;375:985-97.
8. Brott TG, Hobson RW II, Howard G, Roubin GS, Clark WM,
Brooks W, et al, for the CREST Investigators. Stenting versus endar-
terectomy for treatment of carotid-artery stenosis. N Engl J Med
2010;363:11-23.
9. Sidawy AN, Zwolak RM, White RA, Siami FS, Schermerhorn ML,
Sicard GA, for the Outcomes Committee for the Society for Vascular
Surgery. Risk-adjusted 30-day outcomes of carotid stenting and
endarterectomy: results from the SVS Vascular Registry. J Vasc Surg
2009;49:71-9.
10. Giles KA, Hamdan AD, Pomposelli FB, Wyers MC, Schermerhorn ML.
Stroke and death rates after carotid endarterectomy and carotid artery
stenting with and without high risk criteria. J Vasc Surg 2010;52:
1497-504.
11. EVAR Trial Participants. Endovascular aneurysm repair and outcome
in patients unﬁt for open repair of abdominal aortic aneurysm (EVAR
trial 2): randomised controlled trial. Lancet 2005;365:2187-92.
12. Brott TG, Halperin JL, Abbara S, Bacharach JM, Barr JD, Bush RL,
et al. 2011ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/
SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of
Patients With Extracranial Carotid and Vertebral Artery Disease:
a report of the American College of Cardiology Foundation/American
Heart Association Task Force on Practice Guidelines, and the American
Stroke Association, American Association of Neuroscience Nurses,
American Association of Neurological Surgeons, American College of
Radiology, American Society of Neuroradiology, Congress of Neuro-
logical Surgeons, Society of Atherosclerosis Imaging and Prevention,
Society for Cardiovascular Angiography and Interventions, Society of
Interventional Radiology, Society of NeuroInterventional Surgery,
Society for Vascular Medicine, and Society for Vascular Surgery
Developed in Collaboration With the American Academy of Neurology
and Society of Cardiovascular Computed Tomography. J Am Coll
Cardiol 2011;57:1002-44.
13. Blackshear JL, Cutlip DE, Roubin GS, Hill MD, Leimgruber PP,
Begg RJ, et al, for the CREST Investigators. Myocardial infarction after
carotid stenting and endarterectomy: results from the Carotid Revas-
cularization Endarterectomy Versus Stenting Trial. Circulation
2011;123:2571-8.
14. Gurm HS, Yadav JS, Fayad P, Katzen BT, Mishkel GJ, Bajwa TK, et al,
for the SAPPHIRE Investigators. Long-term results of carotid stenting
versus endarterectomy in high-risk patients. N Engl J Med 2008;358:
1572-9.
15. Webster’s New World College Dictionary. 2012 [Internet]. Available
at: http://www.yourdictionary.com/alternative.
16. Paraskevas KI, Veith FJ, Riles TS, Moore WS. Is carotid artery stenting
a fair alternative to carotid endarterectomy for symptomatic carotid
artery stenosis? Eur J Vasc Endovasc Surg 2011;41:717-9.
17. Greenhalgh RM, Brown LC, Powell JT, Thompson SG, Epstein D,
Sculpher MJ, for the United Kingdom EVAR Trial Investigators.
Endovascular versus open repair of abdominal aortic aneurysm. N Engl
J Med 2010;362:1863-71.Submitted Nov 22, 2011; accepted Apr 17, 2012.
